US Stock MarketDetailed Quotes

LYEL Lyell Immunopharma

Watchlist
  • 0.592
  • -0.018-2.95%
Trading Feb 18 10:40 ET
172.99MMarket Cap-0.75P/E (TTM)

Lyell Immunopharma Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Lyell Immunopharma Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
--2024/Q334.000K / 0.000--
--2024/Q213.000K / 0.000--
--2024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
--2024/Q334.000K / 0.000--
--2024/Q213.000K / 0.000--
--2024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

Lyell Immunopharma Earnings Reports

  • Lyell Immunopharma | 10-Q: Q3 2024 Earnings Report

    Nov 7, 2024 16:26 ET

  • Lyell Immunopharma | 8-K: Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

    Nov 7, 2024 16:14 ET

  • Lyell Immunopharma | 10-Q: Q2 2024 Earnings Report

    Aug 7, 2024 22:19 ET

  • Lyell Immunopharma | 8-K: Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

    Aug 7, 2024 16:13 ET

    • Read more

    Trending Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    DexCom
    DXCM
    +4.31%
    New Fortress Energy
    NFE
    +4.36%
    Constellation Brands
    STZ
    +3.90%
    Lantheus
    LNTH
    +3.61%
    Enerpac Tool
    EPAC
    +1.42%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Feb 12, 2025

    Underper form

    • Buy

      0.00%

    • Hold

      50.00%

    • Sell

      50.00%

    Price Target

    No Data